SETTING: An urban tuberculosis control program where an enhanced multidrug-resistant tuberculosis (MDR-TB) management plan coordinated care with multiple providers. OBJECTIVE: To evaluate treatment outcomes of primary MDR-TB patients treated by multiple providers. DESIGN: Retrospective cohort study of tuberculosis patients from 1992-1997 provided that 1) their Mycobacterium tuberculosis isolates were resistant to at least isoniazid and rifampin, and 2) they had had < or = 30 days of anti-tuberculosis treatment prior to the collection of the first MDR-TB specimen. RESULTS: More than 100 facilities and providers reported 856 MDR-TB patients. Treatment completion reached 70% among non-HIV-infected and 30% among HIV-infected persons; 57.2% of the cohort died prior to treatment completion, 26.5% completed treatment, 16.0% transferred out, refused treatment or were lost to follow-up and 0.2% are still in care. Diagnosis in the later years of the study or cavitation on chest radiograph was independently associated with increased completion among HIV-infected patients. Eight of the 227 (3.5%) patients who completed treatment relapsed (relapse rate 1.01/100 person-years), two with drug-susceptible strains. CONCLUSION: A comprehensive MDR-TB control program improved the outcomes of both HIV-infected and non-infected individuals, despite management by multiple providers. Relapse was infrequent among patients who completed the recommended regimens.
SETTING: An urban tuberculosis control program where an enhanced multidrug-resistant tuberculosis (MDR-TB) management plan coordinated care with multiple providers. OBJECTIVE: To evaluate treatment outcomes of primary MDR-TBpatients treated by multiple providers. DESIGN: Retrospective cohort study of tuberculosis patients from 1992-1997 provided that 1) their Mycobacterium tuberculosis isolates were resistant to at least isoniazid and rifampin, and 2) they had had < or = 30 days of anti-tuberculosis treatment prior to the collection of the first MDR-TB specimen. RESULTS: More than 100 facilities and providers reported 856 MDR-TBpatients. Treatment completion reached 70% among non-HIV-infected and 30% among HIV-infectedpersons; 57.2% of the cohort died prior to treatment completion, 26.5% completed treatment, 16.0% transferred out, refused treatment or were lost to follow-up and 0.2% are still in care. Diagnosis in the later years of the study or cavitation on chest radiograph was independently associated with increased completion among HIV-infectedpatients. Eight of the 227 (3.5%) patients who completed treatment relapsed (relapse rate 1.01/100 person-years), two with drug-susceptible strains. CONCLUSION: A comprehensive MDR-TB control program improved the outcomes of both HIV-infected and non-infected individuals, despite management by multiple providers. Relapse was infrequent among patients who completed the recommended regimens.
Authors: Gustavo Ferrer; Carlos Acuna-Villaorduna; Miguel Escobedo; Esteban Vlasich; Manuel Rivera Journal: Am J Trop Med Hyg Date: 2010-11 Impact factor: 2.345
Authors: Dennis Falzon; Neel Gandhi; Giovanni B Migliori; Giovanni Sotgiu; Helen S Cox; Timothy H Holtz; Maria-Graciela Hollm-Delgado; Salmaan Keshavjee; Kathryn DeRiemer; Rosella Centis; Lia D'Ambrosio; Christoph G Lange; Melissa Bauer; Dick Menzies Journal: Eur Respir J Date: 2012-10-25 Impact factor: 16.671
Authors: Mayara L Bastos; Hamidah Hussain; Karin Weyer; Lourdes Garcia-Garcia; Vaira Leimane; Chi Chiu Leung; Masahiro Narita; Jose M Penã; Alfredo Ponce-de-Leon; Kwonjune J Seung; Karen Shean; José Sifuentes-Osornio; Martie Van der Walt; Tjip S Van der Werf; Wing Wai Yew; Dick Menzies Journal: Clin Infect Dis Date: 2014-08-05 Impact factor: 9.079
Authors: Hind Satti; Megan M McLaughlin; Bethany Hedt-Gauthier; Sidney S Atwood; David B Omotayo; Likhapha Ntlamelle; Kwonjune J Seung Journal: PLoS One Date: 2012-10-24 Impact factor: 3.240